Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Equity Average (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Equity Average for 15 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 163.19% to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 163.19% increase, with the full-year FY2024 number at -$5.1 million, down 302.02% from a year prior.
  • Equity Average was $4.0 million for Q3 2025 at Plus Therapeutics, up from -$10.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $14.7 million in Q1 2022 to a low of -$16.3 million in Q1 2025.
  • A 5-year average of $2.3 million and a median of $3.4 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 907.55% in 2021, then plummeted 1208.56% in 2024.
  • Plus Therapeutics' Equity Average stood at $13.4 million in 2021, then crashed by 33.15% to $8.9 million in 2022, then tumbled by 92.86% to $637000.0 in 2023, then tumbled by 1208.56% to -$7.1 million in 2024, then skyrocketed by 157.27% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Equity Average are $4.0 million (Q3 2025), -$10.3 million (Q2 2025), and -$16.3 million (Q1 2025).